“Comparing these results to our Australian Breathe Easy study, we see the result of differing
clinical practices between Australia and the United States, driven by a substantially different healthcare and insurance system. We also see a large number of patients (33%) requiring a third adjudicator, illustrating the difficulty in making a clinical diagnosis even with access to all the tests available in a modern tertiary hospital.”
In a separate announcement a few weeks later as a follow-on to the SmartCough-C2 study
The diagnosis of croup even had a 54% disagreement between adjudicators were a third adjudicator was required can you believe it! You would think with croup the diagnosis would be far easier to distinguish between as I believe kids with croup have a seal bark type of cough and Strider. Not sure how this could be missed 54% of the time?!
Cheers
Red bar
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Builds European Market Presence
Ann: ResApp Builds European Market Presence, page-203
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)